90633-29-7

Basic information

• Product Name: 1-(2,2,2-trifluoroethyl)piperidin-4-ol
• Synonyms: 1-(2,2,2-trifluoroethyl)piperidin-4-ol
• CAS NO: 90633-29-7
• Molecular Formula: C7H12F3NO
• Molecular Weight: 183.1714896
• Mol File: 90633-29-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2,2,2-trifluoroethyl)piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,2,2-trifluoroethyl)piperidin-4-ol(90633-29-7)
• EPA Substance Registry System: 1-(2,2,2-trifluoroethyl)piperidin-4-ol(90633-29-7)

Safety Data

• Hazardous Substances Data: 90633-29-7(Hazardous Substances Data)

Usage

General Description

1-(2,2,2-trifluoroethyl)piperidin-4-ol is a chemical compound that contains a piperidine ring with a fluorinated ethyl group. It is commonly used as an intermediate in organic synthesis and pharmaceutical research. 1-(2,2,2-trifluoroethyl)piperidin-4-ol has potential applications in the development of pharmaceutical drugs, as it may possess therapeutic properties due to its unique chemical structure. Additionally, the trifluoroethyl group can influence the compound's physical and chemical properties, making it valuable for various scientific and industrial purposes. Further research on the biological and chemical properties of 1-(2,2,2-trifluoroethyl)piperidin-4-ol could potentially lead to the discovery of new drugs or materials.

Upstream product

• 81363-14-6 1-(2,2,2-trifluoroethyl)piperidin-4-one oxime 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 6226-25-1 2,2,2-trifluoroethyl trifluoromethanesulphonate 
• 25236-64-0 2,2,2-trifluoroethyl methanesulfonate 

Relevant articles and documents

Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists

CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurological abnormalities in the central nervous system (CNS). Herein, we describe the discovery of a novel 1-cyclopentenyl-3-phenylurea series as potent and CNS penetrant CXCR2 antagonists. Extensive SAR studies, wherein molecules' property forecast index (PFI) was carefully optimized for overall balanced developability profiles, led to the discovery of the advanced lead compound 68 with a desirable PFI. Compound 68 demonstrated good in vitro pharmacology with excellent selectivity over CXCR1 and other chemokine receptors. Rat and dog pharmacokinetics (PK) revealed good oral bioavailability, high oral exposure, and desirable elimination half-life of the compound in both species. In addition, the compound demonstrated dose-dependent efficacy in the in vivo pharmacology neutrophil infiltration "air pouch" model in rodents after oral administration. Further, compound 68 is a CNS penetrant molecule with high unbound fraction in brain tissue.

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.